AAAAAA
Results: 1-25/142
Authors:
KUCZYK MA
SERTH J
BOKEMEYER C
SCHWEDE J
HERRMANN R
MACHTENS S
GRUNEWALD V
HOFNER K
JONAS U
Citation: Ma. Kuczyk et al., THE MXI1 TUMOR-SUPPRESSOR GENE IS NOT MUTATED IN PRIMARY PROSTATE-CANCER, Oncology Reports, 5(1), 1998, pp. 213-216
Authors:
KUCZYK MA
SERTH J
BOKEMEYER C
MACHTENS S
MINSSEN A
BATHKE W
HARTMANN J
JONAS U
Citation: Ma. Kuczyk et al., THE PROGNOSTIC VALUE OF P53 FOR LONG-TERM AND RECURRENCE-FREE SURVIVAL FOLLOWING RADICAL PROSTATECTOMY, European journal of cancer, 34(5), 1998, pp. 679-686
PHASE-I PHARMACOLOGICAL STUDY OF INTRAARTERIALLY INFUSED FOTEMUSTINE FOR COLORECTAL LIVER METASTASES
Authors:
HARTMANN JT
SCHMOLL E
BOKEMEYER C
FETY R
LUCAS C
GIROUX B
SCHMOLL HJ
Citation: Jt. Hartmann et al., PHASE-I PHARMACOLOGICAL STUDY OF INTRAARTERIALLY INFUSED FOTEMUSTINE FOR COLORECTAL LIVER METASTASES, European journal of cancer, 34(1), 1998, pp. 87-91
Authors:
HARTMANN JT
HARSTRICK A
DAIKELER T
KOLLMANNSBERGER C
MULLER C
SEEBER S
KANZ L
BOKEMEYER C
Citation: Jt. Hartmann et al., PHASE-II STUDY OF CONTINUOUS 120 H INFUSION OF MITOMYCIN-C AS SALVAGECHEMOTHERAPY IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER, Anti-cancer drugs, 9(5), 1998, pp. 427-431
Authors:
PONT J
BOKEMEYER C
Citation: J. Pont et C. Bokemeyer, SALVAGE TREATMENT FOR GERM-CELL CANCER AFTER FAILED HIGH-DOSE THERAPY- RESPONSE, Annals of oncology, 9(7), 1998, pp. 788-788
Authors:
KOLLMANNSBERGER C
QUIETZCH D
CLEMENS M
LAMPE C
LINGENFELSER T
HARTMANN JT
KANZ L
BOKEMEYER C
Citation: C. Kollmannsberger et al., A PHASE-II TRIAL OF PACLITAXEL, CISPLATIN, AND WEEKLY 24 H INFUSION OF 5-FLUOROURACIL (5-FU) FOLINIC ACID (FA) IN PATIENTS (PTS) WITH ADVANCED GASTRIC-CANCER/, Annals of oncology, 9, 1998, pp. 229-229
Authors:
HARTMANN JT
NICHOLS CR
DROZ JP
HORWICH A
GERL A
FOSSA SD
BEYER J
PONT J
SCHMOLL HJ
BOKEMEYER C
Citation: Jt. Hartmann et al., EXTRAGONADAL GERM-CELL TUMORS (EGGCT) AND HEMATOLOGIC DISORDERS - INCIDENCE AND OUTCOME FROM AN INTERNATIONAL DATABASE, Annals of oncology, 9, 1998, pp. 268-268
Authors:
KOLLMANNSBERGER C
BOYER J
DROZ JP
HARSTRICK A
HARTMANN JT
BIRON P
FLECHON A
SCHOFFSKI P
KUCZYK M
SCHMOLL HJ
KANZ L
BOKEMEYER C
Citation: C. Kollmannsberger et al., SECONDARY LEUKEMIA FOLLOWING HIGH CUMULATIVE DOSES OF ETOPOSIDE IN PATIENTS TREATED FOR ADVANCED GERM-CELL TUMORS, Journal of clinical oncology, 16(10), 1998, pp. 3386-3391
Authors:
BOKEMEYER C
HARTMANN JT
KUCZYK MA
TRUSS MC
KOLLMANNSBERGER C
BEYER J
JONAS U
KANZ L
Citation: C. Bokemeyer et al., RECENT STRATEGIES FOR THE USE OF PACLITAXEL IN THE TREATMENT OF UROLOGICAL MALIGNANCIES, World journal of urology, 16(2), 1998, pp. 155-162
Authors:
HARTMANN JT
ALBERS P
CLEMM C
SOUCHON R
WEISSBACH L
BAMBERG M
BOKEMEYER C
Citation: Jt. Hartmann et al., REGISTER STUDY FOR THE TREATMENT OF BRAIN METASTASES OF MALIGNANT TESTICULAR-TUMORS, Onkologie, 21(3), 1998, pp. 262-263
Authors:
MACHTENS S
BOKEMEYER C
SERTH J
JONAS U
KUCZYK MA
Citation: S. Machtens et al., ALTERATION OF THE P53 TUMOR-SUPPRESSOR GENE IN PROSTATE-CANCER - ANALYTICAL APPROACHES AND CLINICAL IMPLICATIONS, Onkologie, 21(2), 1998, pp. 113-122
Authors:
BOKEMEYER C
HARSTRICK A
BEYER J
METZNER B
RUTHER U
HARTMANN JT
HOLSTEIN K
DERIGS HG
DEWIT R
CASPER J
SCHOFFSKI P
KUHRER I
ILLIGER HJ
KEMPF B
REICHLE A
FOLLER A
HOSSFELD DK
FISCHER JT
BERDEL W
GERHARTZ H
KIRCHNER H
PFLUGER K
OSTERMANN H
KANZ L
SCHMOLL HJ
Citation: C. Bokemeyer et al., FIRST-LINE HIGH-DOSE CHEMOTHERAPY FOR POOR-RISK METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS, Onkologie, 21, 1998, pp. 23-25
Authors:
KUCZYK MA
KOHN G
HOFNER K
MACHTENS S
BOKEMEYER C
STIEF CG
TRUSS MC
SCHAFERS HJ
HARTMANN JT
JONAS U
Citation: Ma. Kuczyk et al., PROGNOSTIC VALUE OF INTRACAVAL NEOPLASTIC EXTENSION FOR PATIENTS WITHRENAL-CELL CANCER, Der Urologe, 37(3), 1998, pp. 299-305
Authors:
BEYER J
KRAMAR A
MANDANAS R
LINKESCH W
GREINIX A
DROZ JP
PICO JL
DIEHL A
BOKEMEYER C
SCHMOLL HJ
NICHOLS CR
EINHORN LH
SIEGERT W
Citation: J. Beyer et al., PROGNOSTIC FACTORS FOR HIGH-DOSE CHEMOTHERAPY (HDCT) AS SALVAGE TREATMENT IN GERM-CELL TUMORS (GCT), Bone marrow transplantation, 22, 1998, pp. 16-16
Authors:
HARTMANN JT
ALBERS P
CLEMM C
SOUCHON R
WEISSBACH L
BAMBERG M
BOKEMEYER C
Citation: Jt. Hartmann et al., REGISTER STUDY OF PATIENTS WITH CNS METASTASES FROM TESTICULAR GERM-CELL CANCER, Strahlentherapie und Onkologie, 174(6), 1998, pp. 339-339
Authors:
KOLLMANNSBERGER C
HARTMANN JT
KANZ L
BOKEMEYER C
Citation: C. Kollmannsberger et al., RISK OF SECONDARY MYELOID-LEUKEMIA AND MYELODYSPLASTIC SYNDROME FOLLOWING STANDARD-DOSE CHEMOTHERAPY OR HIGH-DOSE CHEMOTHERAPY WITH STEM-CELL SUPPORT IN PATIENTS WITH POTENTIALLY CURABLE MALIGNANCIES, Journal of cancer research and clinical oncology, 124(3-4), 1998, pp. 207-214
Authors:
DOHMEN BM
BOKEMEYER C
OECHSLE K
LIETZENMAYER R
PFANNENBERG AC
BARES R
Citation: Bm. Dohmen et al., PROGNOSTIC VALUE OF FDG-PET PERFORMED BEFORE HIGH-DOSE CHEMOTHERAPY IN GERM-CELL CANCER, The Journal of nuclear medicine, 39(5), 1998, pp. 256-256
Authors:
DOHMEN BM
BOKEMEYER C
OECHSLE K
LIETZENMAYER R
PFANNBERG AC
BARES R
Citation: Bm. Dohmen et al., ACCURACY OF FDG-PET IN CLASSIFICATION OF RESIDUAL TUMOR MASSES AFTER CHEMOTHERAPY OF GERM-CELL CANCER, The Journal of nuclear medicine, 39(5), 1998, pp. 257-257
Authors:
BOKEMEYER C
HARSTRICK A
BEYER J
METZNER B
RUTHER U
HARTMANN JT
HOLSTEIN K
DERIGS HG
DEWIT R
CASPER J
SCHOFFSKI P
KUHRER I
ILLIGER HJ
KEMPF B
REICHLE A
FOLLER A
HOSSFELD DK
FISCHER JT
BERDEL WE
GERHARTZ HH
KIRCHNER H
PFLUGER KH
OSTERMANN H
KANZ L
SCHMOLL HJ
Citation: C. Bokemeyer et al., THE USE OF DOSE-INTENSIFIED CHEMOTHERAPY IN THE TREATMENT OF METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS, Seminars in oncology, 25(2), 1998, pp. 24-32
Authors:
PFANNENBERG AC
DOHMEN BM
BOKEMEYER C
Citation: Ac. Pfannenberg et al., PROGNOSTIC VALUE OF FDG-PET BEFORE HIGH-DOSE (HD) CHEMOTHERAPY (CTX) IN METASTATIC GERM-CELL TUMORS (GCT) - CORRELATION WITH CT AND MRI, Radiology, 209P, 1998, pp. 96-96
Authors:
PFANNENBERG AC
DOHMEN BM
BOKEMEYER C
Citation: Ac. Pfannenberg et al., PROGNOSTIC VALUE OF FDG-PET IN CLASSIFICATION OF RESIDUAL TUMORS AFTER HIGH-DOSE (HD) CHEMOTHERAPY (CTX) OF METASTATIC GERM-CELL TUMORS (GCT), Radiology, 209P, 1998, pp. 97-97
Authors:
HARTMANN JT
KOHNE CH
SCHMOLL HJ
DAIKELER T
KANZ L
BOKEMEYER C
Citation: Jt. Hartmann et al., IS CONTINUOUS 24-HOUR INFUSION OF 5-FLUOROURACIL PLUS HIGH-DOSE FOLINIC ACID EFFECTIVE IN PATIENTS WITH PROGRESSIVE OR RECURRENT COLORECTAL-CANCER - A PHASE-II STUDY, Oncology, 55(4), 1998, pp. 320-325
Authors:
BOKEMEYER C
Citation: C. Bokemeyer, CURRENT TRENDS IN CHEMOTHERAPY FOR METASTATIC NONSEMINOMATOUS TESTICULAR GERM-CELL TUMORS, Oncology, 55(3), 1998, pp. 177-188
Authors:
KUCZYK M
SERTH J
MACHTENS S
BOKEMEYER C
BATHKE W
STIEF EC
JONAS U
Citation: M. Kuczyk et al., EXPRESSION OF E-CADHERIN IN PRIMARY PROSTATE-CANCER - CORRELATION WITH CLINICAL-FEATURES, British Journal of Urology, 81(3), 1998, pp. 406-412
Authors:
BOKEMEYER C
BERGER CC
HARTMANN JT
KOLLMANNSBERGER C
SCHMOLL HJ
KUCZYK MA
KANZ L
Citation: C. Bokemeyer et al., ANALYSIS OF RISK-FACTORS FOR CISPLATIN-INDUCED OTOTOXICITY IN PATIENTS WITH TESTICULAR CANCER, British Journal of Cancer, 77(8), 1998, pp. 1355-1362